MonicaShawMD

Chief, Division of General Internal Medicine, Palliative Medicine and Medical Education at University of L

Dr. Shaw is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
201 Abraham Flexner Way
Louisville, KY 40202
Phone+1 502-589-6788

Fax+1 502-587-4146

University of Louisville School of MedicineResidency, Internal Medicine, 1992 - 1995
University of Louisville School of MedicineClass of 1992

PubMed

1 citations
The Interprofessional Education Exchange: The Impact of a Faculty Development Program in Interprofessional Palliative Oncology Education on Trainee Competencies, Skill...
Tara Schapmire, Barbara Head, Christian Davis Furman, Carol Jones, Bonika Peters
Palliative Medicine Reports. 2021-10-01
4 citations
Teaching Medical Students to Help Patients Manage Their Weight: Outcomes of an Eight-School Randomized Controlled Trial
Judith K. Ockene, Lori Pbert, Sybil L. Crawford, Christine F. Frisard, Jyothi A. Pendharkar
Journal of General Internal Medicine. 2021-04-09
10 citations
Experiential Learning: Transforming Theory into Practice through the Parkinson’s Disease Buddy Program
Denise M. Cumberland, Susan Sawning, Megan Church-Nally, Monica Ann Shaw, Erika Branch
Teaching and Learning in Medicine. 2019-03-12

$Bristol Myers Squibb’s Abecma (Idecabtagene Vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma$
Bristol Myers Squibb’s Abecma (Idecabtagene Vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple MyelomaMarch 21st, 2024
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (Luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)April 3rd, 2024